Roth Capital Keeps Heat Biologics (HTBX) at 'Buy' at Q4 Inflection Points Near
Tweet Send to a Friend
Roth Capital affirms Heat Biologics (Nasdaq: HTBX) at Buy with a price target of $2.75 following Q2 results issued on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
